FF003G 香港聯合交易所有限公司 （香港交易及結算所有限公司的全資附屬公司） 監管表格 上市申請表格 G 表格 GEM 公司資料報表 香港交易及結算所有限公司及香港聯合交易所有限公司對本資料報表的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不對因本資料報表全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任何責任。 公司名稱: Joyzyme Group Limited 愉悅集團有限公司 證券代號 (普通股): 8622 本資料報表列載若干有關上述在香港聯合交易所有限公司（「交易所」）GEM 上市的公司（「該公司」）的資料。該等資 料乃遵照香港聯合交易所有限公司《GEM 證券上市規則》（《GEM 上市規則》）的規定而提供，旨在向公眾提供有關該 公司的資料。該等資料將會在互聯網的 GEM 網頁展示。本資料報表不應視作有關該公司及╱或其證券的完整資料概要。 本報表的資料乃於 二零二六年三月三十日 更新。 A. 一般資料 註冊成立地點: 開曼群島 董事姓名: (請列明董事的身份－執行、非執 行或獨立非執行) 在GEM首次上市日期: 二零一八年十二月十三日 保薦人名稱: 興業金融融 ...

(於開曼群島註冊成立之有限公司) (股份代號: 8622) 非執行董事 卜素博士 獨立非執行董事 周國輝博士 王亞純女士 徐永得先生 董事會已成立三個委員會，而該等委員會的成員如下載列： | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 張玉靜女士 | | – | – | C | | 張春光先生 | | – | M | – | | 周國輝博士 | | M | M | M | | 王亞純女士 | | M | C | M | | 徐永得先生 | | C | – | M | 附註： 董事名單及其角色及職能 愉悅集團有限公司之董事會（「董事會」）成員如下載列： 執行董事 張玉靜女士（聯席主席） 周訓勇博士（聯席主席） 張春光先生 潘禮賢先生（合規主任） 香港，二零二六年三月三十日 C ： 相關董事委員會主席 M ： 相關董事委員會成員 ...

非執行董事之辭任 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立之有限公司) (股份代號: 8622) 愉悅集團有限公司（「本公司」），連同其附屬公司統稱「本集團」）董事（「董事」）會 （「董事會」）謹此宣佈及徐明博士（「徐博士」）為投放更多時間在其個人業務和其他事 務，故而辭任本公司非執行董事，自二零二六年三月三十日起生效。 張玉靜 香港，二零二六年三月三十日 於本公告日期，執行董事為張玉靜女士、周訓勇博士、張春光先生及潘禮賢先生；非執行董 事為卜素博士；及獨立非執行董事為周國輝博士、王亞純女士及徐永得先生。 本公告的資料乃遵照《香港聯合交易所有限公司的 GEM 證券上市規則》而刊載，旨在提供 有 關本公司的資料；董事願就本公告的資料共同及個別地承擔全部責任。各董事在作出一切合 理查詢後，確認就其所知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或 欺詐成分，且並無遺漏任何事項，足以令致本公告或其所載任何陳述產生誤導。 ...

Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 28,282,000, an increase of 7.6% compared to RMB 25,359,000 for the year ended December 31, 2024[6]. - Gross profit for the year was RMB 17,769,000, representing a gross margin of 62.8%, compared to RMB 17,072,000 and a gross margin of 67.3% in the previous year[6]. - Other income increased significantly to RMB 3,311,000 from RMB 698,000, marking a growth of 373.5% year-over-year[6]. - The total comprehensive loss for the year was RMB 4,628,000, slightly higher than the loss of RMB 4,465,000 in the previous year[6]. - The company reported a loss per share of RMB 1.00 for the year ended December 31, 2025, compared to RMB 0.86 in the previous year[7]. - The company reported a pre-tax loss of RMB 5,013 thousand for 2025, compared to a loss of RMB 4,158 thousand in 2024, indicating a deterioration in financial performance[24]. - As of December 31, 2025, the company reported a loss attributable to shareholders of approximately RMB 5.0 million, an increase of about RMB 855,000 or approximately 20.6% compared to the loss of RMB 4.2 million for the year ended December 31, 2024, primarily due to a significant increase in administrative expenses of about RMB 2.3 million[71]. Assets and Liabilities - The company's total assets as of December 31, 2025, were RMB 57,262,000, compared to RMB 54,723,000 in 2024, reflecting a growth of 4.6%[8]. - Current liabilities increased to RMB 14,754,000 from RMB 11,166,000, representing a rise of 32.5% year-over-year[8]. - The net current asset value was RMB 42,508,000, slightly down from RMB 43,557,000 in the previous year[8]. - The company's net asset value as of December 31, 2025, is RMB 51,156,000, compared to RMB 54,048,000 in 2024, reflecting a decrease of approximately 5.4%[9]. - The company's total equity attributable to owners is RMB 51,131,000 in 2025, down from RMB 54,048,000 in 2024, indicating a decline of about 5.4%[9]. - The company's share capital increased to RMB 4,568,000 in 2025 from RMB 4,432,000 in 2024, representing a growth of approximately 3.1%[9]. - The company's reserves decreased to RMB 46,563,000 in 2025 from RMB 49,616,000 in 2024, showing a reduction of about 6.2%[9]. Research and Development - Research and development expenses rose to RMB 3,249,000, up from RMB 2,825,000, indicating a year-over-year increase of 15.0%[6]. - The company plans to continue investing in research and development to enhance its product offerings and market presence[5]. - Research and development expenses increased by approximately RMB 424,000 or 15.0% to approximately RMB 3.2 million for the year ending December 31, 2025, driven by increased employee costs for improving existing products and developing new infertility reagents and health products[69]. Market and Product Strategy - The company is primarily engaged in the research, production, marketing, and sales of biopharmaceuticals and health products in China[11]. - The company plans to continue expanding its market presence and product offerings, focusing on biological agents and health products[23]. - The group aims to transform its women's health division into a comprehensive health service provider, integrating functional supplements with professional nursing services[58]. - The group is strategically targeting the aging population and developing precise anti-aging solutions to meet the growing demand for longevity health[59]. - The group will continue to invest in product development in Canada and China, ensuring expansion plans are tailored to regional regulatory and competitive environments[60]. Shareholder and Corporate Governance - The company has adopted and complied with the corporate governance code as per GEM listing rules during the relevant period[89]. - The company confirms compliance with the minimum public float requirement of 25% under GEM listing rules as of the announcement date[95]. - The audit committee consists of three independent non-executive directors, ensuring compliance with GEM listing rules[102]. - The financial statements have been reviewed and deemed compliant with applicable accounting standards and GEM listing requirements[103]. - The annual report for the year ending December 31, 2025, will be distributed to shareholders and published on the company's website[104]. Employee and Operational Costs - Employee costs, including director remuneration, rose to RMB 17,060,000 in 2025 from RMB 16,153,000 in 2024, reflecting a year-over-year increase of about 5.6%[36]. - The company had 101 full-time employees as of December 31, 2025, an increase from 91 employees in the previous year, with employee costs recognized in profit or loss amounting to approximately RMB 17.1 million[82]. - The company's inventory cost included employee costs, amortization, depreciation, and other lease-related expenses totaling approximately RMB 3,035,000 in 2025, compared to RMB 2,896,000 in 2024, marking an increase of about 4.8%[36]. Acquisitions and Investments - The company acquired 91% of Hunan Keyue Biotechnology Co., Ltd. for a cash consideration of RMB 317,000, enhancing its strategy in the women's health market[50]. - The identifiable net assets of Keyue at the acquisition date were valued at approximately RMB 349,000[52]. - The revenue contribution from Keyue since the acquisition was approximately RMB 2,750,000, with a loss contribution of RMB 77,000[53]. Compliance and Legal Matters - There are no significant legal proceedings or arbitrations involving the company as of December 31, 2025[96]. - The company has not entered into any agreements that would result in the issuance of shares or require the company to enter into any agreements that may lead to share issuance[92]. - The company has not engaged in any purchases, sales, or redemptions of its listed securities during the relevant period[93].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立之有限公司) (股份代號: 8622) 董事會會議通告 香港，二零二六年三月十七日 於本公告日期，執行董事為張玉靜女士、周訓勇博士、張春光先生及潘禮賢先生；非執行董 事為卜素博士及徐明博士；及獨立非執行董事為周國輝博士、王亞純女士及徐永得先生。 本公告的資料乃遵照《香港聯合交易所有限公司的 GEM 證券上市規則》而刊載，旨在提供 有 關本公司的資料；董事願就本公告的資料共同及個別地承擔全部責任。各董事在作出一切合 理查詢後，確認就其所知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或 欺詐成分，且並無遺漏任何事項，足以令致本公告或其所載任何陳述產生誤導。 本公告將自其刊發日期起計最少一連七日刊載於聯交所網站 www.hkexnews.hk 的「最新公司公 告」內。本公告亦將刊載於本公司網站 www.joyzymebiotech.com 愉悅集團有限公司 (「本公司」) 之董事 ...

公司名稱: 愉悅集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08622 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2026年2月28日 | | --- | | 狀態: | | 新提交 | 致：香 ...

香港聯合交易所有限公司 （香港交易及結算所有限公司的全資附屬公司） 監 管 表 格 上市申請表格 G 表 格 GEM 公司資料報表 香港交易及結算所有限公司及香港聯合交易所有限公司對本資料報表的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不對因本資料報表全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 公司名稱: | Joyzyme Group Limited 愉悅集團有限公司 | | --- | --- | | 證券代號 (普通股): | 8622 | 本資料報表列載若干有關上述在香港聯合交易所有限公司（「交易所」）GEM 上市的公司（「該公司」）的資料。該等資 料乃遵照香港聯合交易所有限公司《GEM 證券上市規則》（《GEM 上市規則》）的規定而提供，旨在向公眾提供有關該 公司的資料。該等資料將會在互聯網的 GEM 網頁展示。本資料報表不應視作有關該公司及╱或其證券的完整資料概要。 本報表的資料乃於 二零二六年二月十日 更新。 A. . 一般資料 註冊成立地點: 開曼群島 保薦人名稱: 興業金融融資有限公司 在GEM首次上市日期: 二零一八年十二月十三日 董事 ...

監 管 表 格 上市申請表格 G 表 格 GEM 公司資料報表 香港交易及結算所有限公司及香港聯合交易所有限公司對本資料報表的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不對因本資料報表全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 公司名稱: Joyzyme Group Limited 愉悅集團有限公司 證券代號 (普通股): 8622 本資料報表列載若干有關上述在香港聯合交易所有限公司（「交易所」）GEM 上市的公司（「該公司」）的資料。該等資 料乃遵照香港聯合交易所有限公司《GEM 證券上市規則》（《GEM 上市規則》）的規定而提供，旨在向公眾提供有關該 公司的資料。該等資料將會在互聯網的 GEM 網頁展示。本資料報表不應視作有關該公司及╱或其證券的完整資料概要。 本報表的資料乃於 二零二六年二月九日 更新。 香港聯合交易所有限公司 （香港交易及結算所有限公司的全資附屬公司） 保薦人名稱: 興業金融融資有限公司 董事姓名: (請列明董事的身份－執行、非執 行或獨立非執行) 執行董事 Zhang Yujing (張玉靜) Zhou Xunyong (周訓勇) Z ...

Group 1 - The official registered English name of the company has changed from "Huakang Biomedical Holdings Company Limited" to "Joyzyme Group Limited" effective from January 19, 2026 [1] - The Chinese dual foreign name of the company has changed from "华康生物医学控股有限公司" to "愉悦集团有限公司" effective from January 19, 2026 [1] - The English stock abbreviation on the stock exchange will change from "HUAKANG BIOMED" to "JOYZYME GROUP" effective from 9:00 AM on February 9, 2026 [1] Group 2 - The Chinese stock abbreviation on the stock exchange will change from "华康生物医学" to "愉悦集团" effective from 9:00 AM on February 9, 2026 [1] - The stock code "8622" will remain unchanged on the stock exchange [1] - The company's website will change from "www.huakangbiomedical.com" to "www.joyzymebiotech.com" effective from February 9, 2026 [1]

Group 1 - The official registered English name of the company has changed from "Huakang Biomedical Holdings Company Limited" to "Joyzyme Group Limited" effective from January 19, 2026 [1] - The Chinese dual foreign name of the company has changed from "华康生物医学控股有限公司" to "愉悦集团有限公司" effective from January 19, 2026 [1] - The English stock abbreviation on the Hong Kong Stock Exchange will change from "HUAKANG BIOMED" to "JOYZYME GROUP" effective from 9:00 AM on February 9, 2026 [1] Group 2 - The Chinese stock abbreviation on the Hong Kong Stock Exchange will change from "华康生物医学" to "愉悦集团" effective from 9:00 AM on February 9, 2026 [1] - The stock code "8622" on the Hong Kong Stock Exchange will remain unchanged [1] - The company's website will change from "www.huakangbiomedical.com" to "www.joyzymebiotech.com" effective from February 9, 2026 [1]